Skip to main
HURA

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences is a promising investment opportunity due to its strong pipeline of novel therapies designed to overcome resistance to cancer immunotherapies, including its personalized cancer vaccine IFx-2.0. In addition, its DCF-based valuation methodology gives a total market value of $636M, with a 12-month price objective of $10 per share. However, the company does face risks such as negative clinical results, delays in pipeline advancement, and competition in the checkpoint inhibitor market. Long-term dilution risk should also be considered.

Bears say

TuHURA Biosciences is facing multiple challenges as they enter the final stages of their clinical trials, which may result in a delay of potential FDA approval and commercialization of their key therapies. Additionally, the recent decline in their stock price shows a lack of investor confidence, potentially due to uncertainties surrounding the company's financials and future prospects. While upcoming value inflection points provide opportunities for the stock, the company must navigate these challenges successfully in order to see positive growth. Additionally, the company's reliance on a single reportable segment for all of their activities may pose a significant risk in the event of any setbacks or failures in their clinical trials.

HURA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 3 analysts, HURA has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.